Cannabinoid influence on cytokine profile in multiple sclerosis
S Katona1, E Kaminski, H Sanders
1Department of Immunology, Derriford Hospital, Plymouth PL6 8DH, UK.
Clinical and Experimental Immunology
|June 4, 2005
Summary
Cannabinoids did not impact key immune markers in multiple sclerosis patients. The largest trial to date found no evidence of cannabinoid therapeutic efficacy on immune function in this autoimmune condition.
Area of Science:
- Immunology
- Neuroscience
- Pharmacology
Background:
- Cannabinoids exhibit immunomodulatory properties.
- Cannabinoid receptors are expressed on immune cells like leucocytes.
- Multiple sclerosis (MS) is an autoimmune disease with potential therapeutic targets in cannabinoid research.
Purpose of the Study:
- To evaluate the therapeutic efficacy of cannabinoids in multiple sclerosis patients.
- To investigate the influence of cannabinoids on specific immune markers in MS.
- To assess the impact of cannabinoids on immune cell function in vivo.
Main Methods:
- The Cannabinoids in MS (CAMS) study, a large randomized controlled trial.
- Measurement of serum levels of interferon-gamma, interleukin-10, interleukin-12, and C-reactive protein using ELISA.
- Mitogenic stimulation experiments to assess immune cell response (CD3+, IFN-gamma producing cells) after cannabinoid exposure.
Main Results:
- No significant difference in serum levels of interferon-gamma, interleukin-10, interleukin-12, or C-reactive protein between cannabinoid-treated and control groups.
- Mitogenic stimulation assays showed no significant reduction in CD3+, IFN-gamma producing cells in vivo.
- Observed effects were not statistically significant, potentially due to small sample sizes in specific assays.
Conclusions:
- Current evidence does not support the therapeutic efficacy of cannabinoids in modulating immune responses in multiple sclerosis.
- The functional significance of cannabinoid receptors on immune cells requires further investigation.
- Cannabinoids may not be effective in altering the immune profile of multiple sclerosis patients based on this study.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:28Inflammatory Response
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...